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Abstract
Purpose
The aim of this study was to find useful metabolites to predict lymph node (LN) metastasis in
patients with papillary thyroid cancer (PTC) through a metabolomics approach and investi-
gate the potential role of metabolites as a novel prognostic marker.
Materials and methods
Fifty-two consecutive patients (median age: 41.5 years, range 15–74 years) were enrolled
who underwent total thyroidectomy and central LN dissection with or without lateral LN dis-
section in Severance Hospital between October 2013 and July 2015. The study specimens
were provided by the Severance Hospital Gene Bank, and consisted of PTC from each
patient. The specimens were prepared for proton nuclear magnetic resonance (1H-NMR)
spectroscopy. Spectral data by 1H-NMR spectroscopy were acquired, processed, and ana-
lyzed. Patients were grouped in three ways, according to the presence of LN metastasis,
central LN metastasis and lateral LN metastasis. Chi-square test and the student t-test were
used to analyze categorical variables and continuous variables, respectively. The Mann-
Whitney U test was used for univariate analysis of metabolites. Orthogonal projections to
latent structure discriminant analysis (OPLS-DA) was used for multivariate analysis to dis-
criminate metabolic differences between the two groups.
Results
Among 52 patients, 32 had central LN metastasis and 19 had lateral LN metastasis. No
clinical or histopathological characteristic was significantly different for all comparisons. On
univariate analysis, no metabolite showed significant difference for all comparisons. On mul-
tivariate analysis, OPLS-DA did not discriminate the presence and absence of LN metasta-
sis. Lactate was found to be the most promising metabolite.
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Conclusions
No metabolite could discriminate the presence of LN metastasis. However, lactate was
found to be the most promising metabolite for discrimination. Further studies with larger
sample sizes are needed to elucidate significant metabolites which can indicate the pres-
ence of LN metastasis in patients with PTC.
Introduction
The incidence of thyroid cancer has increased worldwide during the last few decades and it is
now the most common endocrine malignancy [1,2]. Papillary thyroid cancer (PTC) is the
most common histologic type, accounting for 85% to 90% of thyroid malignancies [3]. Most
patients with PTC have excellent prognosis, with the 10-year survival rate being about 90%
[3,4]. However, some patient subsets suffer from more aggressive PTC characterized by recur-
rent disease, lymph node (LN) or distant metastasis [5]. These patients may need more exten-
sive surgery including total thyroidectomy with therapeutic or prophylactic LN dissection and
postoperative radioactive iodine (RAI) ablation [6]. Therefore, being able to predict risk is
important and would help stratify patients for proper treatment [7].
Several prognostic factors have been discovered including patient age at diagnosis, size and
extent of the primary tumor, cervical LN metastasis, and occurrence of distant metastasis [8,9].
Of these prognostic factors, it is LN metastasis that is associated with an increased incidence of
recurrence [10]. The incidence of central and lateral LN metastasis has been reported about
50–60% and 4.1–42.6%, respectively depending on the study [11–13]. Ultrasound plays main
role in detection and characterization of cervical LN and ultrasound-guided fine-needle aspi-
ration biopsy (FNAB) is the main diagnostic tool for the diagnosis of metastatic cervical LN in
patient with PTC [14].However even under ultrasound guidance, approximately 5–10% of the
FNAB results of cervical LN might be nondiagnostic and 6–8% might be false negative [15].
Advances in genetic research and molecular biology have discovered several genetic
changes behind thyroid cancer [16]. The RAS mutation, RET/PTC rearrangement, and
PAX8-peroxiome proliferator-activated receptor γ1 fusion are important oncogenic genetic
alterations in thyroid cancer [17–19]. Also, the BRAFV600E mutation results from a single thy-
mine-to-adenosine transversion which is a high specific marker for PTC [7,20]. The
BRAFV600E mutation is useful when diagnosing PTC, especially in cases in which the cytologic
results only provide suspicious results for PTC [21]. However, the association between the
BRAFV600E mutation and LN metastasis remains under question [22–24].
Metabolomics is a new field in biological science, which uses analytic tools in conjunction
with pattern recognition approaches and bioinformatics [25]. The metabolome is the final
downstream product of gene expression; thus, it reflects changes in the transcriptome and the
proteome [26]. Alterations in metabolic processes occur during carcinoma development and
progression, along with histologic and cytologic changes [27]. Understanding the biochemistry
of cancer may enable the development of powerful diagnostic tools and the identification of
new biomarkers [28]. Several studies have proven that the metabolomics approach allows the
characterization of different types of malignancies in other organs [29–31]. For example, the
presence of 2-hydroxyglutarate which is a metabolite detected by magnetic resonance spectros-
copy (MRS) correlated with mutations in isocitrate dehydrogenase 1 or 2 (IDH1, 2) in patients
with gliomas of the brain [32]. IDH1 or IDH2 mutation is an significant marker of positive
prognosis and chemosensitivity [33]. In patients with breast cancer, the combined magnetic
Metabolomic approach in papillary thyroid carcinoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0193883 March 6, 2018 2 / 11
resonance (MR) protocol of dynamic contrast-enhanced MR imaging and proton nuclear
magnetic resonance (1H-NMR) spectroscopy improved sensitivity and specificity in the diag-
nosis of breast cancer [30].
Several studies have applied metabolomics to PTC [34,35]. To our knowledge, little is
known about the association between metabolomics and the presence of LN metastasis in
PTC. The aim of our study was to investigate metabolic differences according to the presence
or absence of LN metastasis in patients with PTC in the search for a potential novel prognostic
marker.
Materials and methods
This study was approved by the Institutional Review Board of Severance Hospital, Yonsei Uni-
versity College of Medicine in Seoul, Korea.
Patients and sample collection
Patients who underwent total thyroidectomy and central LN dissection with or without lateral
LN dissection in Severance Hospital between October 2013 and July 2015 were enrolled
in this study. The specimens for this study were provided by the Severance Hospital Gene
Bank, and consisted of conventional PTC from each patient. All samples were obtained
with informed consent under institutional review board-approved protocols. Samples were
snap-frozen in liquid nitrogen immediately after surgery and then stored at −70˚C. All of the
data were securely protected while being made available only to investigators and analyzed
anonymously.
Preparation of tissue extracts
Frozen thyroid samples were finely ground in a mortar under liquid nitrogen. Percholoric acid
(4%; 1:4, w/v) was added to each sample, followed by centrifugation at 20000 ɡ for 15 min. The
supernatant was transferred to a new tube where chloroform/tri-n-octylamine (78%/22%; v/v)
was added in a 1:2 volumetric ratio to increase the pH to ~6. The samples were centrifuged at
20000 ɡ for 15 min. The aqueous phase was removed and transferred to a microfuge tube, and
then lyophilized. 200L of deuterium oxide (99.96%; Cambridge Isotope Laboratories) was
added to each sample and the pH was adjusted to 7.0 with 0.2-1L of 1M sodium deuteroxide
(99.5%; Cambridge Isotope Laboratories). The pH-neutral samples were then centrifuged at
15000 ɡ for 1 min., and the supernatant was then removed and placed in a 3-mm NMR tube
for subsequent NMR analysis.
Proton NMR spectroscopy
1H-NMR spectroscopy was performed on a Bruker Advanc spectrometer (Bruker Instruments,
Billerica, MA) operating at a proton NMR frequency of 700.40 MHz (16.45 Tesla). A one-
dimensional CPMG (Carr-Purcell-Meiboom-Gill) pulse sequence was used to obtain thyroid
metabolite profiles with a 90 degree pulse length of about 7 μs. The water signal was suppressed
using a selective excitation pulse followed by a pulsed field gradient in the z-axis. The spectral
acquisition parameters were as follows: 16K complex data points, 8417 Hz sweep width, 2.0 s
acquisition time, 2.0 s relaxation delay, 1.5 s presaturation time (5.5 s total time of repetition
(TR)), 1.0 ms interpulse delay (2 ms time of echo (TE)), 32 number of transients, 20.2 receiver
gain and total acquisition time of 5 min. An experimental line broadening function of 0.2 Hz
and automatic zero-filing of a factor of 2 was applied to each FID prior to Fourier transforma-
tion. 1H-NMR spectra were manually corrected for phase and baseline distortion using
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TOPSPIN 3.5 (Bruker Instruments, Billerica, MA) and referenced to the trimethylsilyl propi-
onic acid (TSP) signal (0.0 ppm).
Data and statistical analysis
All 1H-NMR spectra were processed and analyzed using Chenomx NMR Suite 7.7 software
(Chenomx, Edomonton, Canada). Post-processing consisted of Fourier transformation, phas-
ing and baseline correction. Chemical shifts were referenced to TSP at 0.0 ppm. Spectral
regions from 0.5 to 9.0 ppm [Isoleucine (Iso), Leucine (Leu), Valine (Val), Threonine (Thr),
Lactate (Lac), Alanine (Ala), Uracil (Ura), Lysine (Lys), Glutamate (Glu), Methionine (Met),
Aspartate (Asp), Free choline (Cho), Phosphocholine (PC), Glycerophosphocholine (GPC),
Taurine (Tau), Myo-inositol (m-Ins), Glycine (Gly), Phosphoethanolamine (PE), Inosine
(Ino), Tyrosine (Tyr), Hypoxanthine (Hyp), Formate (For), Succinate (Suc), and Uridine
(Uri)] were selected for quantification. The peak amplitudes of the metabolites were measured
by fitting a Voigt (e.g., Gauss+Lorentz) line-shape function. Metabolites [mM] were quantified
by comparing the integrated TSP signal to the metabolite signal.
Patients were grouped into two groups in three different ways, according to the following
factors: the presence or absence of LN metastasis, central LN metastasis, and lateral LN metas-
tasis. Normality was assessed using the Kolmogorov-Smirnov test. Chi-square analysis was
used to analyze categorical variables and the student t-test was used to analyze continuous vari-
ables. 1H-NMR spectroscopic data were analyzed using the Mann-Whitney U test because the
results of the Kolmogorov-Smirnov test were statistically significant (p-value<0.05), which
indicated that the data did not follow a normal distribution.
For multivariate analysis of spectral data, Matlab R2012a (MathWorks, Natick, MA), SIM-
CA-P version-13.0 software (Umetrics, Sweden), and Excel (Microsoft, Seattle, WA) programs
were used. The spectral data were normalized to the total spectral area. The spectral region
between 0.5 and 10 ppm was divided into bins of 0.01 ppm width. The water region from
4.6 ppm to 4.9 ppm was excluded prior to analysis. The binned data were aligned using the ico-
shift algorithm in Matlab [36], and were converted to the SIMCA-P format in Excel. Pareto
scaling was used to preprocess the data. The intensity of each metabolite was normalized to the
total intensity before statistical analysis. Orthogonal projections to latent structure discrimi-
nant analysis (OPLS-DA) is one of the popular methods for multivariate analysis in metabolo-
mics [37]. Before OPLS-DA was performed, data were variable stability (VAST) scaled, with
the standard deviation and the variation coefficients of the metabolites as scaling factors [38].
OPLS-DA were performed to maximize the separation between the two groups of interest. Sta-
tistical analyses were conducted using statistical software (R, Statistical Package version 3.3.3;
R Foundation for Statistical Computing, Vienna, Austria; www.R-project.org). The muma
package was used to perform OPLS-DA [39].
Results
Tissue samples were available from 52 patients during the study period. The median age of the
patients was 41.5 years (range 15–74 years). Twelve patients were male and 40 were female.
The median tumor size was 23 mm (range 13–40 mm). Among the patients, 32 had central LN
metastasis and 19 had lateral LN metastasis. All patients with lateral LN metastasis had central
LN metastasis as well, thus the results of comparison in two ways, according to the presence or
absence of LN metastasis and central LN metastasis were identical. Therefore the comparisons
were analyzed in two ways according to the presence or absence of LN metastasis or the pres-
ence or absence of lateral LN metastasis. Four patients had distant metastasis.
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No clinical or histopathological characteristic was significantly different for all comparisons
when the patients were classified into two groups according to the presence or absence of LN
metastasis or the presence or absence of lateral LN metastasis. Patient demographics and histo-
pathological characteristics are shown in Table 1.
1H-NMR spectroscopy quantified 24 metabolites in normal and PTC tissues. On univariate
analysis, no metabolite showed significant difference between the two groups classified accord-
ing to the presence or absence of LN metastasis or the presence or absence of lateral LN metas-
tasis (Table 2).
OPLS-DA was performed to separate patients into two groups for each comparison.
OPLS-DA score plots did not separate the two groups clearly for all three comparisons. When
patients were classified according to the presence or absence of LN metastasis and central LN
metastasis, the OPLS-DA score plot exhibited nonseparation between the two groups (A in Fig
1). The corresponding OPLS-DA loading S-plot showed lactate which was located in the left
lower section of the S-plot as the most important metabolite to discriminate the two groups (B
in Fig 1). When patients were classified according to the presence or absence of lateral LN
metastasis, the OPLS-DA score plot exhibited nonseparation between the two groups (A in Fig
2) and the corresponding OPLS-DA loading S-plot showed that lactate in the left lower section
of the S-plot and myo-inositol in the right upper section were the most important metabolites
to discriminate the two groups (B in Fig 2).
Discussion
The aim of this study was to explore metabolic differences in PTC according to the presence or
absence of LN metastasis. We found that no metabolite could discriminate the two groups.
However, lactate was found to be the most promising metabolite for discrimination.
Metabolomics is the analytic study of the metabolome, which differs in cancer cells and rep-
resents alteration of metabolic processes, and understanding the metabolome will allow deeper
understanding of carcinoma development [27]. Several previous studies have applied metabo-
lomics to PTC. In earlier times, studies were conducted to identify metabolic differences
between thyroid neoplasms and normal thyroid tissue [34]. Normal thyroid tissue presented a
higher level of lipids as well as lower levels of alanine, lactate and choline compared to neoplas-
tic tissue [34].
Subsequent studies focused on discriminating benign and malignant thyroid neoplasms
such as follicular adenoma or goiter nodules [40,41]. Recent studies further revealed that NMR
spectroscopy could be applied to percutaneous FNA samples [42,43]. In these studies,
Table 1. Patient demographics and clinicopathologic characteristics.
Variable Total LN metastasis P-value Lateral LN metastasis P-value
(+) (-) (+) (-)
Number of patients 52 32 (61.5%) 20 (38.5%) 19 (36.5%) 33 (63.5%)
Age 41.5 (15–74) 37 (15–66) 42.5 (16–74) 0.328 35 (15–60) 43 (16–74) 0.139
Gender
Male 12 (23.1%) 7 5 0.795 6 13 0.270
Female 40 (76.9%) 25 15 6 27
Primary tumor size (mm) 23 (13–40) 23 (13–40) 23 (14–37) 0.563 20 (13–40) 23 (14–37) 0.895
Distant metastasis 4 (7.7%) 4 0 0.100 4 0 0.014
Note–Unless otherwise specified, the data are the medians (range).
LN, lymph node.
https://doi.org/10.1371/journal.pone.0193883.t001
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malignant thyroid nodules were found to show higher relative concentrations of lactate and
choline [43]. The results indicated that the NMR spectra of FNA cytology samples were similar
to those of surgical specimens; hence, it had the potential to detect and classify thyroid tumors
before surgery [42]. Furthermore, there was an attempt to discriminate nodular thyroid disease
by analyzing urine and serum using 1H-NMR spectroscopy [44]. In this study, metabolomics
could discriminate healthy controls from non-neoplastic nodules, follicular adenoma and PTC
[44]. Increased lactate levels were observed in the blood serum of patients with nodular thyroid
disease compared to healthy controls [44].
To our knowledge, this was the first research to discriminate the presence of metastatic LN
in patients with PTC using 1H-NMR spectroscopy. Although our results failed to discriminate
patients with and without LN metastasis, our data suggested the possibility of lactate being the
most promising metabolite to predict LN metastasis. Lactate has been previously reported to
increase in cancer [45]. Lactate reflects two important characteristics of biological changes that
occur in tumor metabolism. First, tumor hypoxia shifts cellular energy production toward gly-
colysis from which lactate is generated as a by-product [45]. Second, it reflects aerobic glycoly-
sis which tumors exhibit even if oxygen is present [46]. The importance of lactate is that it may
indicate a more aggressive tumor phenotype that expresses LN metastasis in cancers of other
Table 2. Comparison of metabolites obtained by 1H-NMR spectroscopy between patient groups classified by the presence of lymph node metastasis and lateral
lymph node metastasis.
Metabolite concentration (mM) LN metastasis P-value Lateral LN metastasis P-value
(+) (-) (+) (-)
Isoleucine 0.02 (0.01–0.47) 0.03 (0.00–0.47) 0.821 0.02 (0.01–0.16) 0.02 (0.00–0.47) 0.924
Leucine 0.05 (0.01–0.16) 0.06 (0.01–1.02) 0.880 0.05 (0.01–0.41) 0.05 (0.01–1.02) 0.761
Valine 0.06 (0.02–0.34) 0.06 (0.02–0.79) 0.940 0.05 (0.02–0.34) 0.06 (0.02–0.80) 0.642
Lactate 1.70 (0.61–10.51) 1.57 (0.39–7.11) 0.328 1.66 (0.61–10.51) 1.70 (0.39–7.11) 0.500
Threonine 0.07 (0.04–2.97) 0.08 (0.03–0.97) 0.873 0.07 (0.04–2.97) 0.08 (0.03–0.97) 0.518
Alanine 0.15 (0.04–0.58) 0.14 (0.03–1.50) 0.940 0.13 (0.04–0.58) 0.16 (0.03–1.50) 0.635
Uracil 0.02 (0.01–0.09) 0.02 (0.01–0.12) 0.461 0.03 (0.01–0.09) 0.16 (0.01–0.12) 0.218
Lysine 0.07 (0.02–0.56) 0.10 (0.01–1.15) 0.918 0.12 (0.02–0.56) 0.06 (0.01–1.15) 0.337
Glutamate 0.25 (0.08–2.51) 0.29 (0.04–2.53) 0.665 0.25 (0.10–0.56) 0.25 (0.04–2.53) 0.601
Methionine 0.04 (0.01–0.16) 0.04 (0.01–0.25) 0.397 0.04 (0.01–0.16) 0.04 (0.01–0.25) 0.655
Aspartate 0.07 (0.02–0.52) 0.06 (0.01–0.67) 0.288 0.07 (0.02–0.52) 0.07 (0.01–0.67) 0.464
Choline 0.03 (0.01–0.22) 0.03 (0.01–0.19) 0.714 0.03 (0.01–0.22) 0.03 (0.01–0.19) 0.635
Phosphocholine 0.19 (0.04–1.04) 0.20 (0.05–0.72) 0.925 0.21 (0.04–0.99) 0.19 (0.04–1.04) 0.655
Glycerophosphocholine 0.06 (0.02–616.00) 0.07 (0.02–0.25) 0.880 0.06 (0.03–0.41) 0.06 (0.02–616.0) 0.842
Taurine 0.55 (0.16–1.58) 0.50 (0.08–2.39) 0.763 0.52 (0.24–1.58) 0.50 (0.08–2.39) 0.512
Myo-inositol 1.21 (0.27–4.71) 1.40 (0.24–4.25) 0.652 1.14 (0.27–4.71) 1.25 (0.24–4.25) 0.798
Glycine 0.14 (0.04–0.98) 0.14 (0.04–2.06) 0.585 0.11 (0.04–0.98) 0.15 (0.04–2.06) 0.992
Phosphoethanolamine 0.35 (0.05–0.1.88) 0.54 (0.11–1.61) 0.560 0.31 (0.11–1.88) 0.44 (0.05–1.61) 0.992
Inosine 0.02 (0.00–0.13) 0.02 (0.00–0.12) 0.301 0.02 (0.00–0.13) 0.02 (0.00–0.13) 0.909
Tyrosine 0.02 (0.00–0.16) 0.02 (0.00–0.44) 0.893 0.02 (0.01–0.16) 0.02 (0.00–0.44) 0.270
Hypoxanthine 0.02 (0.00–0.16) 0.04 (0.01–0.51) 0.293 0.03 (0.01–0.16) 0.02 (0.00–0.51) 0.585
Formate 0.20 (0.01–0.89) 0.13 (0.00–0.48) 0.185 0.19 (0.05–0.89) 0.15 (0.00–0.48) 0.275
Succinate 0.02 (0.01–0.76) 0.03 (0.00–0.52) 0.297 0.02 (0.01–0.76) 0.02 (0.00–0.52) 0.790
Uridine 0.01 (0.00–0.02) 0.01 (0.00–0.02) 0.917 0.01 (0.00–0.02) 0.01 (0.00–0.23) 0.551
Note–Unless otherwise specified, the data are the medians (range).
LN, lymph node.
https://doi.org/10.1371/journal.pone.0193883.t002
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organs [45,47]. In this study, lactate stood out as the most promising metabolite to represent
the group with LN metastasis [47].
There are some limitations to this study. First, it is a retrospective study. Second, we per-
formed ex vivo spectroscopy using surgical specimens. In vivo 1H-NMR spectroscopy is the
most optimal diagnostic method for the preoperative diagnosis of thyroid nodules and predic-
tion of prognosis. However, as performing in vivo 1H-NMR spectroscopy can be complicated
by various issues such as thyroid movement during respiration or shimming difficulty due to
large susceptibility differences between the neck and air in trachea, we decided to perform ex
vivo 1H-NMR spectroscopy [48]. Third, our study was done with a small sample size and the
Fig 1. (Left) OPLA-DA score plot for lymph node metastasis. Red dots represent patients with lymph node metastasis
and black dots represents patient without lymph node metastasis. The x-axis is the first component from OPLS-DA
and the y-axis is the corresponding orthogonal score. (Right) OPLS-DS loading S-plot for lymph node metastasis. The
x-axis is the covariation and the y-axis is the corresponding orthogonal score. The metabolites situated at the upper
right or lower left sections are statistically relevant and represent possible discriminating variables.
https://doi.org/10.1371/journal.pone.0193883.g001
Fig 2. (Left) OPLA-DA score plot for lateral lymph node metastasis. Red dots represent patients with lateral lymph
node metastasis and black dots represents patient without lateral lymph node metastasis. The x-axis is the first component
from OPLS-DA and the y-axis is the corresponding orthogonal score. (Right) OPLS-DS loading S-plot for lateral lymph
node metastasis. The x-axis is the covariation and the y-axis is the corresponding orthogonal score. The metabolites
situated at the upper right or lower left sections are statistically relevant and represent possible discriminating variables.
https://doi.org/10.1371/journal.pone.0193883.g002
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proportion of patients with LN metastasis was relatively high which may explain the failure to
discriminate LN metastasis.
In spite of these limitations, our data suggest that lactate may be used to predict LN metas-
tasis and prognosis. Further studies with larger sample sizes are needed to elucidate significant
metabolites which can indicate the presence of LN metastasis in patients with PTC.
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